Translating Novel & Transformational Analgesics into the Clinic

One year on from Vertex Pharmaceuticals' milestone JOURNAVX® approval, making history as the first new class of pain medicine in decades, non-opioid pain R&D has skyrocketed as one of biopharma’s hottest areas for innovation and investment, projected to hit $124bn by 2034. M&A headlines, including Eli Lilly's $1bn+ acquisitions of SiteOne Therapeutics and 4E Therapeutics, AbbVie's $745m licensing deal with Haisco Pharmaceutical, continue to fuel the pain innovation flywheel.

As companies race to build on the first major clinical validation of the space, attention is rapidly expanding beyond sodium channels as a ‘silver bullet’ toward neuroimmune pathways, neurotrophin biology, GLP-1 signaling, potassium channels, gene regulation, and other emerging mechanisms.

Bringing together 150+ senior leaders across pain biology, drug discovery, translational science, clinical development, medical affairs, business development, venture capital, and patient advocacy, the 2nd Non-Opioid Pain Therapeutics Summit is the ultimate forum for drug developers to advance the next generation of pain medicines. Join experts from Vertex Pharmaceuticals, Eli Lilly, AbbVie, Grünenthal, Xenon Pharmaceuticals, Levicept, Tonix Pharma, Maxona Pharmaceuticals, 4E Therapeutics, NIH, Harvard Medical School, and leading investment firms to explore emerging mechanisms, new clinical data, trial design innovations, placebo mitigation strategies, translational models, patient-centered development approaches, and the investment trends shaping the future of pain therapeutics.

discovery, translational, clinical, and commercial functions have become essential.